66. IgA nephropathy
199 clinical trials,   214 drugs   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000075-33-DE
(EUCTR)
19/12/201901/07/2019OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden
2EUCTR2018-000075-33-GB
(EUCTR)
06/11/201927/06/2019OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Philippines;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Germany;Sweden;Korea, Republic of
3EUCTR2018-000075-33-AT
(EUCTR)
15/11/201825/06/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
450Phase 3United States;Philippines;Taiwan;Slovakia;Spain;Lithuania;Austria;Hungary;Czech Republic;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Sweden;Korea, Republic of
4EUCTR2018-000075-33-BE
(EUCTR)
03/10/201831/05/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Omeros CorporationNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
450Phase 3United States;Philippines;Taiwan;Slovakia;Spain;Lithuania;Austria;Hungary;Czech Republic;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Sweden;Korea, Republic of
5EUCTR2018-000075-33-PL
(EUCTR)
17/09/201810/07/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2018-000075-33-CZ
(EUCTR)
06/09/201806/04/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Philippines;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Germany;Sweden;Korea, Republic of
7EUCTR2018-000075-33-BG
(EUCTR)
05/09/201819/07/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden
8EUCTR2018-000075-33-SE
(EUCTR)
03/09/201803/05/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Taiwan;Slovakia;Thailand;Spain;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Sweden;Korea, Republic of
9EUCTR2018-000075-33-ES
(EUCTR)
01/08/201821/05/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
434Phase 3United States;Slovakia;Spain;Lithuania;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Bulgaria;Germany;Sweden
10EUCTR2018-000075-33-SK
(EUCTR)
21/06/201820/04/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN)
MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Philippines;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Germany;Sweden;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2018-000075-33-LT
(EUCTR)
15/06/201823/04/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721
INN or Proposed INN: OMS721
Other descriptive name: OMS721
Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3United States;Taiwan;Slovakia;Thailand;Spain;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden
12EUCTR2018-000075-33-HU
(EUCTR)
07/06/201829/03/2018OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: OMS721Omeros CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
434Phase 3United States;Hungary;Canada;Australia
13NCT03608033
(ClinicalTrials.gov)
February 16, 201821/6/2018Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)IgA NephropathyBiological: OMS721;Other: Vehicle (D5W or saline)Omeros CorporationNULLRecruiting18 YearsN/AAll450Phase 3United States;Australia;Austria;Belgium;Bulgaria;Hungary;Lithuania;Poland;Slovakia;Spain
14NCT02682407
(ClinicalTrials.gov)
February 201610/2/2016Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit DiseaseIgAN;Lupus Nephritis;MN;C3 GlomerulopathyBiological: OMS721 (narsoplimab)Omeros CorporationNULLRecruiting18 YearsN/AAll54Phase 2United States;Hong Kong